Subscribe to NRx Newsletter
Hope Therapeutics

Hope Therapeutics, an NRx Pharma daughter company, is developing NRX-100 (IV Ketamine) for treatment of Acute Suicidality and Depression. 

Learn more about how we are bringing hope to 3.5 million lives in the United States. A copy of our recent presentations are available below.

View our keynote address at the Sachs Neuroscience Forum on Jan 7, 2024:


For further information please contact: 

Matthew Duffy, Chief Business Officer,
Jonathan C. Javitt, M.D., M.P.H. Chairman and Chief Scientist,